| 09:00 |
|
| 10:00 |
|
| 11:00 |
|
| 12:00 |
|
| 13:00 |
[13:30] IMBB - ICS Open Lecture
- Description:
- Paramet Summer School - Computational Sciences in Drug Discovery
Ulka VIJAPURKAR
Center for Discovery and Innovation in Parasitic Diseases
Department of Pathology, University of California San Francisco
Title: "Principles of Drug Development: Discovery and Development of a small molecule inhibitor to a kinase target for oncology".
Wednesday, July 2nd 2014 @ 13:30 (note that the lecture starts exactly at 13:30)
Seminar Room 1, FORTH's bldg
Information: Inga Siden-Kiamos (inga@imbb.forth.gr), Ioannis Tsamardinos (tsamard@ics.forth.gr)
Abstract:
In the last few years there has been an intense effort towards the development of small molecule inhibitors targeting various nodes of the PI3K/mTOR signaling pathways with several currently undergoing clinical evaluation as anti-cancer agents. mTOR, a component of two protein complexes mTORC1 and mTORC2, is a critical target in the PI3K/Akt signaling axis and a central nexus integrating PI3K, MAPK and other signaling pathways. It controls various aspects of cell physiology, most importantly, regulation of translation. It is a clinically validated target with allosteric mTORC1 inhibitors, rapamycin and its analogs, having been approved for several indications. Second generation kinase inhibitors of mTOR, which target both the mTORC 1 and 2 complexes, are in clinical development and have the potential to be more potent anti-cancer drugs. However their clinical efficacy and clinical niche remains to be determined.
In my lecture I will discuss the development of a small molecule kinase inhibitor of the mTOR protein. I will discuss investigation of its mechanism of action, studies to identify biomarkers of sensitivity to mTOR inhibition that would help to prioritize indications for its clinical development and lastly, combination strategies with inhibitors of upstream or parallel signaling nodes such as PI3K or MAPK that could have implications for rational combinations strategies in the clinic for selected patient populations.
I will discuss this specific project within the context of the preclinical drug development process and my experience working with cross-functional project teams such as chemistry, assay development, pharmacology and clinical in a biotechnology industry environment. I will end the lecture with a brief discussion from a personal perspective on the role of women in science and industry and challenges faced by many in the quest to balance life and family with demanding careers.
--------------------------------------------------------------------------------
Short Bio:
Dr. Vijapurkar received her Ph.D. in molecular pharmacology from the University of Iowa, Iowa city, U.S.A. After completing her post-doctoral fellowship from the University of California, San Francisco she moved to the biotech industry and was a research scientist at Genentech/Roche for several years. Currently she is adjunct Professor at the University of San Francisco, where she teaches advanced physiology, pharmacogentics and molecular medicine to students in the M.S. Biotech program.
|
| 14:00 |
|
| 15:00 |
[15:30] IMBB Open Lecture
- Description:
- DENDRITES 2014 -- 4th NAMASEN Training Workshop on Dendrites
Susumu TONEGAWA, Nobel Laureate
Picower Professor of Biology and Neuroscience
Director, RIKEN-MIT, Center for Neural Circuit Genetics
Picower Institute for Learning and Memory, Massachusetts Institute of Technology
Director, RIKEN Brain Science Institute
Title: "Control of temporal association memory by feedforward dendritic inhibition".
Wednesday, July 2nd 2014 @ 15:30 (note that the lecture starts exactly at 15:30)
Georgios Lianis Amphitheater, FORTH's bldg
Information: Yiota Poirazi (poirazi@imbb.forth.gr)
--------------------------------------------------------------------------------
Short Bio:
Dr. Susumu Tonegawa received his Ph.D. from UCSD. He then undertook postdoctoral work at the Salk Institute in San Diego, before working at the Basel Institute for Immunology in Basel, Switzerland, where he performed his landmark immunology experiments. Tonegawa won the Nobel Prize for Physiology or Medicine in 1987 for “his discovery of the genetic principle for generation of antibody diversity”. He has since continued to make important contributions but in an entirely different field: neuroscience. Using advanced techniques of gene manipulation, Tonegawa is now unraveling the molecular, cellular and neural circuit mechanisms that underlie learning and memory. His studies have broad implications for psychiatric and neurologic diseases. Tonegawa is currently the Picower Professor of Biology and Neuroscience at the Massachusetts Institute of Technology (MIT) and the Director of the RIKEN-MIT Center for Neural Circuit Genetics at MIT as well as the Director of RIKEN Brain Science Institute.
|
| 16:00 |
|
| 17:00 |
|
| 18:00 |
|
| 19:00 |
|
| 20:00 |
|
| 21:00 |
|
July 2014
